Share with your friends

Deal Capsule - October 2017

Deal Capsule - October 2017

M&A activity remains solid in life sciences.



Christian Klingbeil

Partner, Deal Advisory - Valuation

KPMG AG Wirtschaftsprüfungsgesellschaft


Related content


Theme of this issue:

M&A activity remains solid in life sciences with a high number of announced deals, although deal values are not expected to hit the heady levels of 2014 and 2015. Oncology drives M&A in life sciences as key players seek to optimize their portfolios in anticipation of 10.9% CAGR growth to 2030. Chemical companies are increasingly focussing their M&A on application industries. Agrochemicals remains an M&A hotspot. The closing of the DowDuPont merger brought with it a spate of anti-trust divestments. US and China remain the most active countries in both sectors.

Online version

Browse directly through the publication

KPMG Deal Capsule Newsletter

© 2020 KPMG AG Wirtschaftsprüfungsgesellschaft, a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. All rights reserved.

KPMG International Cooperative (“KPMG International”) is a Swiss entity.  Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.

Connect with us


Want to do business with KPMG?


loading image Request for proposal